AYTU Biopharma (AYTU) risk factors
Item 1A of every AYTU Biopharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors59 risks2 dropped5 reworded
Customer concentration increased to five customers representing 83% of fiscal 2026 gross revenue, versus four customers representing 85% previously.
Filed Sep 22, 2026 - FY2025 10-K risk factors61 risks4 new14 dropped14 reworded
Aytu Biopharma added four new risks concerning third-party component supply, payor reimbursement, patent litigation, and macroeconomic volatility. The company highlighted ongoing EXXUA commercialization and updated significant shareholder ownership stakes.
Filed Sep 23, 2025 - FY2024 10-K risk factors71 risks
Aytu relies heavily on commercializing its pediatric and ADHD prescription portfolios amid persistent operating losses and significant accumulated deficits. The company depends on single-source suppliers and third-party manufacturers, posing supply chain and regulatory vulnerabilities. Compliance with DEA regulations for controlled substances and strict healthcare pricing rules are critical to operations.
Filed Sep 26, 2024